Running Clinical Trials in Kenya as a Contract Research Organization: A Compliance Guide

Running clinical trials in Kenya as a contract research organization means operating inside someone else’s regulatory approval, not building one of your own. Kenyan law does not create a separate CRO licence; a CRO instead has to make sure the sponsor’s trial clears every gate the Pharmacy and Poisons Board and Kenya’s research-governance system require, in the right order, before a single patient is enrolled. Getting that sequence wrong is the most common way a promising trial stalls before it starts.

The Regulatory Framework

Clinical trials in Kenya sit under the Pharmacy and Poisons Act (Cap. 244) and the Pharmacy and Poisons (Conduct of Clinical Trials) Rules, 2022, with the Board’s own Guidelines for the Conduct of Clinical Trials, 2022 setting out the operational detail. The Pharmacy and Poisons Board is the authorising body for every trial conducted in the country, and it runs a dedicated Clinical Trials Registry System through which any person intending to carry out a trial is required to submit their application. There is no shortcut around this system for a CRO managing the operational side of a study on a sponsor’s behalf; the CRO’s job is to get the sponsor’s application through it correctly.

Sequencing: Ethics Review Before PPB Authorisation

The step CROs most often get wrong is trying to run ethics review and PPB authorisation in parallel. They cannot be run together. A trial first needs approval from a NACOSTI-accredited institutional scientific and ethics review committee, of which KEMRI’s Scientific and Ethics Review Unit is the best known, before a PPB application can even be submitted. Only once that favourable ethics opinion is in hand does the PPB review begin. After PPB authorisation, the study still needs a NACOSTI research licence before it can actually start; a non-Kenyan investigator applying for that licence needs an affiliation with a Kenyan institution to do so.

A PPB submission package typically needs to include the study protocol, the ethics committee’s approval letter, the Investigator’s Brochure, GMP manufacturing certification for the investigational product, insurance or indemnity cover for participants, investigator CVs showing Good Clinical Practice training, data safety monitoring board arrangements, and financial and conflict-of-interest declarations. A CRO assembling this package should treat it as a single coordinated submission rather than a set of documents gathered as they become available, since PPB reviews the file as a whole.

Dual Registration Before Submission

Kenya requires a trial to be registered in two places, and one of them has to happen before the PPB application goes in. The Pan African Clinical Trials Registry registration is expected to be in place before PPB submission, and the trial also needs to be entered into PPB’s own Clinical Trials Registry System. For a CRO running several studies at once, treating registry entry as an early, fixed milestone rather than an afterthought avoids a submission bouncing back for a missing registration number.

What a CRO Is, Legally, in This Framework

Kenyan pharmaceutical law does not carve out a distinct licensing category for contract research organizations the way it does for manufacturers, distributors, or laboratories. A CRO operating in Kenya is, in regulatory terms, the sponsor’s delegated agent for the trial, and it is the sponsor’s authorisation that the CRO is executing against, not a separate CRO authorisation. That does not mean a CRO can operate informally. It still needs to be properly incorporated and registered as a business in Kenya to contract, invoice, and employ staff here, and it needs its own quality systems and standard operating procedures robust enough to satisfy a PPB inspection, since the Board’s ongoing oversight of a trial reaches the CRO’s conduct of it even without a CRO-specific licence sitting behind that oversight.

Staying Compliant Once a Trial Is Running

PPB authorisation is not a one-time event for the life of the study. Investigators are expected to keep their study details on the Board’s registry updated on an ongoing basis, and ongoing trials are required to submit a checklist for annual approval rather than relying on the original authorisation indefinitely. A trial run without PPB authorisation, or allowed to lapse out of compliance with that ongoing reporting obligation, risks having its data treated as unreliable for any later product registration built on it, on top of the direct regulatory exposure of running an unauthorised trial. For a CRO, that makes the annual renewal checklist and registry updates a compliance deadline worth calendaring with the same seriousness as the original submission.